Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)
Article in Trials (March 2024)
The most recent citing publications are shown below. View all 29 publications that cite this research output on Dimensions.
Article in Trials (March 2024)
Article in Clinical Immunology (September 2023)
Article in HLA (July 2023)